Search





Search





Markets
/
Stocks
/
nasdaq-ctmx
/

CytomX Therapeutics Inc

CTMX

Add to Watchlist

3.610USD

-0.170-4.50%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

785.91MMarket Cap

LossP/E TTM



CytomX Therapeutics Inc

3.610

-0.170-4.50%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of CytomX Therapeutics Inc

Currency: USD Updated: 2026-05-15

Key Insights

CytomX Therapeutics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 34 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.12.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

CytomX Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

34 / 382

Overall Ranking

130 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

CytomX Therapeutics Inc Highlights

StrengthsRisks

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The Company is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors.

Growing

The company is in a growing phase, with the latest annual income totaling USD 76.20M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 76.20M.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Undervalued

The company’s latest PE is -6.93, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 165.85M shares, decreasing 7.73% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 59.72K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.25.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

13.125

Target Price

+247.22%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of CytomX Therapeutics Inc is 7.42, ranking 88 out of 382 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 10.26M, representing a year-over-year decrease of 79.85%, while its net profit experienced a year-over-year decrease of 177.57%.

Score

Industry at a Glance

Previous score

7.42

Change



Financials

6.52

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.89

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.50

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.20

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

CytomX Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of CytomX Therapeutics Inc is 8.80, ranking 17 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -6.93, which is -451.67% below the recent high of 24.38 and -5025.51% above the recent low of -355.38.

Score

Industry at a Glance

Previous score

8.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 34/382

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

The current earnings forecast score of CytomX Therapeutics Inc is 8.89, ranking 37 out of 382 in the Biotechnology & Medical Research industry. The average price target is 6.50, with a high of 10.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

8.89

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

13.125

Target Price

+247.22%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

CytomX Therapeutics Inc

CTMX

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Ionis Pharmaceuticals Inc

IONS

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of CytomX Therapeutics Inc is 6.71, ranking 177 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 4.59 and the support level at 3.10, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.76

Change

-0.05

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.078

Sell

RSI(14)

29.919

Sell

STOCH(KDJ)(9,3,3)

8.668

Oversold

ATR(14)

0.216

High Vlolatility

CCI(14)

-164.115

Sell

Williams %R

96.250

Oversold

TRIX(12,20)

-0.695

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

3.784

Sell

MA10

3.929

Sell

MA20

4.163

Sell

MA50

4.460

Sell

MA100

4.765

Sell

MA200

3.918

Sell

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of CytomX Therapeutics Inc is 7.00, ranking 83 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 78.87%, representing a quarter-over-quarter decrease of 19.41%. The largest institutional shareholder is Steven Cohen, holding a total of 10.86M shares, representing 4.99% of shares outstanding, with 50.85% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

20.19M

+54.43%

VR Adviser, LLC

15.56M

Longitude Capital Management Co., LLC

11.54M

Point72 Asset Management, L.P.

Star Investors

5.19M

+27.55%

Perceptive Advisors LLC

9.68M

Kynam Capital Management LP

8.97M

+145.88%

Commodore Capital LP

7.69M

State Street Investment Management (US)

5.14M

+697.07%

Baker Bros. Advisors LP

4.25M

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of CytomX Therapeutics Inc is 4.13, ranking 99 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 2.13. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.